Literature DB >> 32582954

IL-37d Negatively Regulates NLRP3 Transcription via Receptor-mediated Pathway and Alleviates DSS-induced Colitis.

Yuan Li1, Hongxia Chu1, Mingsheng Zhao1, Chaoze Li1, Yetong Guan1, Chun Guo1, Yan Li1,2, Qun Wang1, Yongyu Shi1, Faliang Zhu1, Lining Zhang1.   

Abstract

BACKGROUND: Interleukin-37 (IL-37) is a new negative immune regulator. It has 5 splicing forms, IL-37a-e, and most research mainly focuses on IL-37b functions in diverse diseases. Our previous research found that IL-37d inhibits lipopolysaccharide-induced inflammation in endotoxemia through a mechanism different from that of IL-37b. However, whether IL-37d plays a role in colitis and the underlying mechanisms is still obscure. Herein, we identified whether IL-37d regulates NLRP3 inflammasome activity and determined its effect on colitis.
METHODS: NLRP3 inflammasome in macrophages from IL-37d transgenic (IL-37dtg) and control wild type (WT) mice were activated by lipopolysaccharide and adenosine 5'-triphosphate. The expression of NLRP3 inflammasome components and its downstream effector, IL-1β, were detected by real-time polymerase chain reaction, western blot, and ELISA. The models of alum-induced peritonitis and dextran sodium sulfate (DSS)-induced colitis were used to investigate the function of IL-37d on regulating the activity of NLRP3 inflammasome in vivo.
RESULTS: Our results showed that the activation of NLRP3 inflammasome in macrophage and alum-induced peritonitis was inhibited by IL-37d. Strikingly, IL-37d suppressed NLRP3 expression at the priming step via inhibiting NF-κB activation by transcriptional profiling. Moreover, the recombinant protein IL-37d attenuated NLRP3 inflammasome activation and the production of IL-1β, which could be reversed by IL-1R8 knockdown. Finally, IL-37d transgenic mice resisted DSS-induced acute colitis and NLRP3 inflammasome activation.
CONCLUSION: Interleukin-37d inhibits overactivation of the NLRP3 inflammasome through regulating NLRP3 transcription in an IL-1R8 receptor-mediated signaling pathway.
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  interleukin-37 isoform D; DSS-induced colitis; IL-1R8; NLRP3 inflammasome; alum-induced peritonitis

Year:  2021        PMID: 32582954     DOI: 10.1093/ibd/izaa124

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

1.  IL-1R8 as Pathoimmunological Marker for Severity of Canine Chronic Enteropathy.

Authors:  Federica Riva; Laura Bianchessi; Camilla Recordati; Alessia Inglesi; Vittoria Castiglioni; Lauretta Turin
Journal:  Vet Sci       Date:  2022-06-14

2.  Interleukin-37 exacerbates experimental colitis in an intestinal microbiome-dependent fashion.

Authors:  Junxiao Cong; Dandan Wu; Hanying Dai; Yanmei Ma; Chenghui Liao; Lingyun Li; Liang Ye; Zhong Huang
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

3.  IL-37b alleviates endothelial cell apoptosis and inflammation in Kawasaki disease through IL-1R8 pathway.

Authors:  Chang Jia; Yingzhi Zhuge; Shuchi Zhang; Chao Ni; Linlin Wang; Rongzhou Wu; Chao Niu; Zhengwang Wen; Xing Rong; Huixian Qiu; Maoping Chu
Journal:  Cell Death Dis       Date:  2021-06-03       Impact factor: 8.469

4.  IL-37 isoform D acts as an inhibitor of soluble ST2 to boost type 2 immune homeostasis in white adipose tissue.

Authors:  Chaoze Li; Mingsheng Zhao; Ming Zhao; Nuo Chen; Yaxin Guo; Yingxin Du; Yi Zhang; Baihui Cao; Bing Zhan; Chun Guo; Yuan Li; Yan Li; Yongyu Shi; Faliang Zhu; Lining Zhang; Qun Wang
Journal:  Cell Death Discov       Date:  2022-04-05

Review 5.  Negative Regulation of the IL-1 System by IL-1R2 and IL-1R8: Relevance in Pathophysiology and Disease.

Authors:  Domenico Supino; Luna Minute; Andrea Mariancini; Federica Riva; Elena Magrini; Cecilia Garlanda
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 6.  Current Understanding of IL-37 in Human Health and Disease.

Authors:  Zhangci Su; Xiaoan Tao
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.